Agomab reports positive OLE data for ontunisertib in Crohn's bowel strictures
The company said results from the 48-week extension study support starting a global Phase 2b trial, NOV-ERA, in the coming months.
SEC filing
Latest
4 stories
Today
Monday, September 14
Agomab reports positive Phase 1 data for inhaled IPF drug AGMB-447, plans Phase 2
The company submitted a clinical trial application for a 120-patient Phase 2 study called INSPIRIA and expects to start it in the second half of 2026.
SEC filing
Monday, August 10
Agomab proposes Marino Garcia and Dr. Naimish Patel for board seats
Belgium-based Agomab Therapeutics plans to add the two as non-executive directors, pending a shareholder vote in September 2026.
SEC filing
Thursday, August 6
Agomab reports first-half 2026 results, confirms FDA alignment on Crohn's trial design
The company said cash of €252 million should fund operations into the first half of 2029 as it prepares to start two new studies later this year.
SEC filing